Miguel-Angel Berciano-Guerrero

11PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsMedical bacteriologyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 07, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

|Sep 12, 2024
Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review.

Mora Guardamagna, May-Lucie Meyer, Miguel Ángel Berciano-Guerrero

|Oct 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.

Philip Clingan, Rahul Ladwa, Daniel Brungs

|Aug 03, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.

Sarah A Weiss, Mario Sznol, Montaser Shaheen

|Oct 27, 2022
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.

Javier Oliver, Juan Luis Onieva, Maria Garrido-Barros

|Oct 14, 2022
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.

Mora Guardamagna, Miguel-Angel Berciano-Guerrero, Beatriz Villaescusa-González

Pageof 2

Frequent Collaborators

7 joint publications

Elisabeth Perez-Ruiz

3 joint publications

Isabel Barragán

3 joint publications

Javier Oliver

3 joint publications

Juan-Luis Onieva-Zafra